Nobuki Matsunami
Overview
Explore the profile of Nobuki Matsunami including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
87
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fukada I, Ito Y, Kondo N, Ohtani S, Hattori M, Tokunaga E, et al.
Breast Cancer Res Treat
. 2021 Sep;
190(3):425-434.
PMID: 34554370
Purpose: The sequence of taxanes (T) followed by anthracyclines (A) as neoadjuvant chemotherapy has been the standard of care for almost 20 years for locally advanced breast cancer (LABC). Sequential...
2.
Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, et al.
Invest New Drugs
. 2020 Aug;
39(1):217-225.
PMID: 32833136
Purpose To date, it is not clear which anticancer agent is useful in combination with trastuzumab and pertuzumab As the first and second selective regimens for advanced or metastatic breast...
3.
Ishiguro H, Masuda N, Sato N, Higaki K, Morimoto T, Yanagita Y, et al.
Breast Cancer Res Treat
. 2020 Mar;
180(3):715-724.
PMID: 32170634
Purpose: Our primary objective was to determine the benefit/risk of anthracycline-free regimens by comparing docetaxel + cyclophosphamide (TC) alone, fluorouracil + epirubicin + cyclophosphamide (FEC) followed by TC, or TC...
4.
Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, et al.
Jpn J Clin Oncol
. 2019 Dec;
50(1):3-11.
PMID: 31821506
Background: The original aim of this study was to evaluate the treatment sequence and anthracycline requirement in docetaxel, cyclophosphamide and trastuzumab therapy. After one death in the anthracycline-containing arm, the...
5.
Iwasa T, Tsurutani J, Watanabe S, Kato R, Mizuno Y, Kojima Y, et al.
BMC Cancer
. 2019 Oct;
19(1):962.
PMID: 31619197
Background: We previously reported the synergistic effect of S-1 and eribulin in preclinical models. In addition, our phase I study revealed the recommended dose for the phase II study of...
6.
Tanaka S, Matsunami N, Morishima H, Oda N, Takashima T, Noda S, et al.
Cancer Chemother Pharmacol
. 2019 Apr;
83(6):1099-1104.
PMID: 30963212
Purpose: Neoadjuvant trastuzumab combined with anthracycline and taxane is now considered a standard regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A less toxic, non-anthracycline regimen has...
7.
Kimura K, Iwamoto M, Tanaka S, Yamamoto D, Yoshidome K, Ogura H, et al.
Cancer Chemother Pharmacol
. 2018 Mar;
81(5):923-933.
PMID: 29594360
Purpose: Although eribulin is a suitable option for early-line treatment of metastatic breast cancer (MBC), data on first- or second-line use of eribulin for human epidermal growth factor receptor 2...
8.
Nakayama T, Sagara Y, Takashima T, Matsunami N, Masuda N, Miyoshi Y, et al.
Cancer Chemother Pharmacol
. 2018 Feb;
81(4):755-762.
PMID: 29468454
Purpose: This phase II study evaluated the efficacy and safety of anastrozole concurrent with tegafur/uracil (UFT) as neoadjuvant therapy for ER-positive postmenopausal breast cancer. Methods: Postmenopausal Japanese women with ER-positive,...
9.
Ohtani S, Nakayama T, Yoshinami T, Watanabe K, Hara F, Sagara Y, et al.
Breast Cancer
. 2018 Feb;
25(4):438-446.
PMID: 29435730
Background: This study aimed to investigate whether schedule modification is safe and effective in patients intolerant to the standard eribulin dose and schedule. Methods: Patients with metastatic breast cancer (MBC)...
10.
Yamamura J, Masuda N, Yamamoto D, Tsuyuki S, Yamaguchi M, Tanaka S, et al.
Chemotherapy
. 2017 Jun;
62(5):307-313.
PMID: 28605730
Background: This phase II study was conducted to evaluate the efficacy and safety of the chemotherapy combination of gemcitabine and vinorelbine in taxane-pretreated Japanese metastatic breast cancer patients. Methods: In...